Bayer Augments Thrombosis Pipeline by Licensing ISIS-FXIRx from Isis Pharmaceuticals
By Heather Cartwright & Rohit Khera; Heather Cartwright & Rohit Khera
Pharma Deals Review: Vol 2015 Issue 5 (Table of Contents)
Published: 22 May-2015
DOI: 10.3833/pdr.v2015.i5.2103 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to strengthen its already robust position in the thrombosis market, Bayer HealthCare has licensed exclusive worldwide rights to develop and commercialise Isis Pharmaceuticals’ ISIS-FXIRx, an antisense Factor XI in Phase II development that is designed to prevent blood clots without significantly increasing the risk of bleeding...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS